latest news releases from the newsroom
TASER International, Inc.
TASER International, Inc. Reports Results for Third Quarter 2008
SCOTTSDALE, Ariz., Oct. 28, 2008 (GLOBE NEWSWIRE) -- TASER International, Inc. (Nasdaq:TASR) ("TASER" or "the Company"), a market leader in advanced electronic control devices (ECD), today reported financial results for the fiscal third quarter ended September 30, 2008.
Occidental Petroleum Corp.
Occidental Petroleum Announces Third Quarter Net Income
LOS ANGELES, Oct. 28, 2008 (GLOBE NEWSWIRE) -- Occidental Petroleum Corporation (NYSE:OXY) announced net income of $2.271 billion ($2.78 per diluted share) for the third quarter of 2008, compared with $1.324 billion ($1.58 per diluted share) for the third quarter of 2007.
DealerTrack Holdings, Inc.
DealerTrack Launches 'Manage' Module to Round Out Its Comprehensive Accessories Solution
LAKE SUCCESS, N.Y., Oct. 28, 2008 (GLOBE NEWSWIRE) -- DealerTrack Accessories Solutions, Inc., a subsidiary of DealerTrack Holdings, Inc. (Nasdaq:TRAK), a leading provider of on-demand software and data solutions for the U.S. automotive retail industry, today announced the addition of its new "Manage" module to the DealerTrack Accessories Solution. With this enhancement, the DealerTrack Accessories Solution is the most comprehensive in the industry and provides auto dealers with the tools to increase their share of the large and highly profitable accessories business.
Web.com Partners With PowerPay to Provide Payment Processing Solutions to eCommerce Customers
JACKSONVILLE, Fla. and PORTLAND, Maine, Oct. 28, 2008 (GLOBE NEWSWIRE) -- Web.com (Nasdaq:WWWW), a leading provider of online marketing for small businesses, and PowerPay, a rising star in the electronic payments industry, today announced a partnership that will provide PowerPay's payment processing solutions to Web.com's eCommerce customers. Under the agreement, Web.com will offer its eCommerce customers payment processing solutions, coupled with enhanced fraud detection and card security compliance features, which can significantly lower their credit card processing fees by up to 25%.
Chelsea Therapeutics Completes Enrollment in Phase II Trial of CH-1504 in Rheumatoid Arthritis
CHARLOTTE, N.C., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a novel metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients.